title: Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
abstract: The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm2) and 17.4 mg/24 h (20 cm2)] and oral capsules (3 to 6 mg twice-daily). Patients entering the extension were switched directly to 9.5 mg/ 24 h rivastigmine patch and increased to 17.4 mg/24 h patch, irrespective of their double-blind study treatment. Primary measures included safety and tolerability assessments, including adverse events and serious adverse events. Of 1195 patients randomized to treatment, 870 (72.8%) completed the double-blind study and entered the open-label extension. During weeks 1 to 4 of the extension, 9.5 mg/24 h rivastigmine patch was well tolerated overall by patients formerly randomized to rivastigmine capsule or patch groups: < or =2.5% reported nausea and < or =1.9% reported vomiting. No unexpected safety issues arose, and skin tolerability was good; similar to the double-blind study. During the 28-week, open-label extension phase, the patch seemed to be well tolerated with a favorable safety profile.
authors.affiliation: Department of Neurology and Psychiatry, St Louis University School of Medicine, 1438 South Grand Boulevard, St. Louis, MO 63104, USA. Grossbgt@aol.com
authors.forename: George
authors.initials: G
authors.lastname: Grossberg
authors.forename: Carl
authors.initials: C
authors.lastname: Sadowsky
authors.forename: Hans
authors.initials: H
authors.lastname: Fröstl
authors.forename: Lutz
authors.initials: L
authors.lastname: Frölich
authors.forename: Jennifer
authors.initials: J
authors.lastname: Nagel
authors.forename: Sibel
authors.initials: S
authors.lastname: Tekin
authors.forename: Stefanie
authors.initials: S
authors.lastname: Zechner
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Ros
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Orgogozo
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D048448:Phenylcarbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068836:Rivastigmine; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine